Cabaletta Bio (CABA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Annual Meeting scheduled for June 9, 2026, with participation via live webcast.
Supplement updates the original proxy statement filed on April 28, 2026.
Record date for voting eligibility is April 20, 2026.
Voting matters and shareholder proposals
Proposal 3, regarding an amendment to the 2019 Stock Option and Incentive Plan, has been withdrawn and will not be considered.
All other proposals (1, 2, 4, 5, and 6) remain on the agenda and will be voted as directed.
Proxy cards or instructions for Proposal 3 will not be counted; no need to resubmit proxies unless changing votes on remaining proposals.
Board of directors and corporate governance
Board decided to withdraw Proposal 3 after discussions with management and advisors.
Board reserves the right to propose future amendments to the equity compensation plan.
Latest events from Cabaletta Bio
- Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption.CABA
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Durable, safe cell therapy shows promise for autoimmune diseases, enabling outpatient access.CABA
Jefferies Global Healthcare Conference 20264 Jun 2026 - Rese-cel demonstrates robust efficacy and safety, enabling scalable outpatient therapy for autoimmunity.CABA
Corporate presentation3 Jun 2026 - Automated CAR T manufacturing and preconditioning-free regimens drive scalable autoimmune therapy.CABA
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Rese-cel delivers durable, safe, and scalable CAR T therapy for autoimmune diseases.CABA
Corporate presentation14 May 2026 - Q1 2026 net loss was $43.5M; $141M and $150M financings extend runway into mid-2027.CABA
Q1 202614 May 2026 - Rese-cel delivers durable, safe, outpatient CAR T therapy for autoimmune diseases at scale.CABA
Corporate presentation28 Apr 2026 - Key votes include director elections, stock plan and share increase, and auditor ratification.CABA
Proxy filing28 Apr 2026 - Shareholders will vote on key governance, compensation, and capital structure proposals at the annual meeting.CABA
Proxy filing28 Apr 2026